Friends! In this video, I'm going to analyze big tech stocks like Microsoft, Amazon, Google, Meta and discuss their capex.
3 extracted signals · 3 resolved · 0 still active
The Patient Investor18 Feb 2026, 00:32 UTC
AI-generated source summary
The analysis focuses on the current market downturn, attributing the decline in major tech stocks like Microsoft, Amazon, and Meta to fears around capital expenditures. The presenter argues that while some fear is warranted, the market's reaction might be overblown. They highlight Amazon's historical performance and ongoing growth in cash flow from operations, suggesting that despite high capex, the company has consistently delivered strong returns. The presenter also contrasts the growth strategies of companies with high versus low capex, noting that companies like Meta, while investing heavily in capex, are doing so to drive future growth and maintain market position. The overall sentiment is that while the market sentiment is negative, the underlying fundamentals of these companies remain strong, indicating potential investment opportunities.
AI-generated summary based on the source content.
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
3 eligible signals linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
Signals in this source
More Prediction Case Files from The Patient Investor
Why I Don't Own Google Stock & When I'm Buying
The CHEAPEST Quality Stock In The Stock Market!
Intuitive Surgical Stock Analysis! Risks & Upside Potential
There Is NO AI BUBBLE! I’m Buying Every Dip
2 Stocks I'm Buying In The Next 2 Weeks
Netflix Stock Is FINALLY A Buy!
The Patient Investor
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.


